Page 8 - Vol. 39-No.4 issue

FOOD PRODUCTS AND PROCESSING EQUIPMENT

ARLA FOODS INGREDIENTS SQUEEZES MORE

PROTEIN INTO JUICE-STYLE SUPPLEMENTS

Arla Foods Ingredients has developed per 100g and is high in essential amino
a new solution to increase the protein acids, including leucine (1.13g per 100g).
content of juice-style oral nutrition sup- Juice-style medical drinks made with
plements (ONS) for medical nutrition. The Lacprodan® BLG-100 are an excellent
concept will be on show at the forthcoming source of protein and energy. The new
Vitafoods Europe (May 9th to 11th). solution is fat-free and the use of BLG-
Most ONS are milky beverages, but 100 enables very low viscosity and stability
recent years have seen juice-style drinks over shelf life. In addition, it tastes less
emerge as a fresh-tasting alternative. astringent than typical ONS juice-style
However, such products remain niche, products and provides a more pleasant
accounting for just 3.7% of adult liquid mouthfeel, encouraging compliance in
ONS launches over the past five years.* medical nutrition.
One reason for this might be that the av- Troels Nørgaard Laursen, Director for
erage protein content of ONS juice-style Health & Performance at Arla Foods In-
drinks is just 4.2g per 100g.
gredients, said: “Juice-style options are a
Arla Foods Ingredients has now created a promising alternative to traditional milky
solution that makes it possible to increase oral nutritional supplements, but there has
the level of protein in ONS juice-style drinks been room for improvement when it comes Arla Foods Ingredients will Other con-
to 7% without compromising on taste or to their protein profile. Lacprodan® BLG- cepts on show will include innovative solu-
mouthfeel. The new concept incorporates 100 is a great solution to this challenge. It’s tions for high-protein ready-to-drink tea
Lacprodan® BLG-100, a 100% pure be- rich in essential amino acids – in particular and coffee, and a multi-textured bar with
ta-lactoglobulin with an outstanding nu- leucine – and helps ONS deliver a more protein in every layer, a special edition of
tritional profile. It contains 7g of protein palatable drinking experience.” which has been created for Vitafoods.
Circle 6 on enquiry card
SPOREVIA PROBIOTIC CAN REDUCE STAPH

COLONISATION BY OVER 95%, STUDY FINDS

Kerry Group’s probiotic strain Sporev- 2021. The double-blind, randomized, pla- effects or significant microbiome changes.
ia (Bacillus subtilis MB40) can eliminate cebo-controlled trial was conducted fol- According to the researchers, the findings
Staphylococcus aureus in the human body lowing the discovery that Sporevia secretes indicate potential for Bacillus subtilis to be
by more than 95%, a clinical trial has found. fengycin, which has been shown to inhibit used to lower infection rates in vulnerable
S. aureus colonisation. individuals, and in long-term care facilities
One hundred and fifteen adults from such as nursing homes.
Thailand took part in the study, which was "We were delighted to have Sporevia se-
funded by the US National Institutes of lected for this study," says John Menton,
Health and the National Research Council PhD, Senior Product Director, Digestive
of Thailand. All were colonised by S. aureus, Health, at Kerry Group. "We have long
either in the intestine, nose, or both, but understood the power of spore-forming
had no history of intestinal disease, an- probiotics to produce metabolites, enzymes
tibiotic treatment, or hospital admission and, depending on the strain, fengycins
Staphylococcus aureus (S. aureus), com- within the previous 90 days.2 which may inhibit the growth of deleteri-
monly known as 'staph', is a pathogen that They received either 250 mg of Spor- ous bacteria. In this case the study found
caused over 119,000 infections and nearly evia* (10 billion CFU) or placebo once a that Sporevia produces higher amounts
20,000 deaths in the US in 2017.1 How- day for 30 days, after which S. aureus of fengycins than other probiotic strains
ever, the use of oral antibiotics for staph colonisation was determined. Oral sup- considered for the study, which made it a
decolonisation is advised against because plementation with Sporevia resulted in a great candidate for further research. While
of its effect on the gut microbiota and an- 96.8% reduction of S. aureus in the stool we’re not surprised by the conclusions, it’s
tibiotic resistance.2 and a 65.4% reduction of S. aureus in the always great to see hypotheses based on
Sporevia (Bacillus subtilis MB40) is a nose whereas there were no significant in vitro and animal model data supported
probiotic strain owned by Kerry Group differences in the placebo groups. by clinical trial results. This study is very
following the licensing agreement with Furthermore, these levels of decolo- encouraging as it demonstrates Sporevia’s
the company BIO-CAT Microbials in June nization were achieved without adverse potential in bacteria management."

6 Vol. 39 No. 4 Circle 7 on enquiry card